When Does Onglyza's Patent Expire?
Onglyza (saxagliptin), made by AstraZeneca and Bristol-Myers Squibb, has key U.S. patents expiring in 2025–2026. The primary compound patent (U.S. Patent 6,995,180) ends October 2025, with pediatric exclusivity adding six months to mid-2026. Some formulation patents extend to 2032, but generics could launch after the main ones expire if no further delays occur.[1][2]
Is a Generic Available Now?
No FDA-approved generic saxagliptin exists as of 2024. AstraZeneca has defended patents against challenges from Mylan, Lupin, and others via ANDA filings, but settlements or court rulings could allow entry by late 2025. Check FDA's Orange Book for updates on Paragraph IV challenges.[2]
How Much Does Onglyza Cost Without Insurance?
Brand-name Onglyza 5 mg (30 tablets) lists at $500–$600 monthly, though coupons from GoodRx or manufacturer savings cards drop it to $50–$100 for eligible patients. Prices vary by pharmacy and location.[3]
Will Generics Slash Costs—and By How Much?
Generics typically cut prices 80–90% once launched. Expect saxagliptin generics at $50–$100 monthly without insurance, similar to other DPP-4 inhibitors like Januvia generics (now ~$20–$40). Multiple competitors will drive competition.[1][4]
Should You Wait for Generic If Cost Is Your Main Concern?
If you're stable on Onglyza and can afford it short-term via discounts, waiting until mid-2026 might save hundreds yearly—but don't skip doses, as uncontrolled blood sugar risks complications. Switching now to cheaper alternatives avoids gaps. Consult your doctor for personalized risks.[5]
Cheaper Alternatives to Onglyza Right Now
- Other DPP-4 inhibitors: Generic linagliptin (Trajenta, ~$20–$50/month) or sitagliptin (Januvia generic, ~$20–$40).
- GLP-1s or SGLT2s: Semaglutide (Ozempic/Wegovy generics pending 2026+), empagliflozin (Jardiance generic 2028), or metformin combos—all cheaper generics available.
- Lifestyle + generics: Metformin ($4/month) or sulfonylureas often match efficacy for many type 2 diabetes patients at fraction of cost.[5][6]
| Drug | Brand Cost/Month | Generic Cost/Month | Patent Expiry |
|------|------------------|--------------------|---------------|
| Onglyza (saxagliptin) | $500–$600 | N/A yet (~$50 expected) | 2025–2026 |
| Januvia (sitagliptin) | $500+ | $20–$40 | 2026 |
| Tradjenta (linagliptin) | $500+ | $20–$50 | 2025 |
What Could Delay Generic Onglyza?
Ongoing litigation or new patents might push entry to 2027+. AstraZeneca settled some ANDAs for 2025 launches, but others remain in court. Track via DrugPatentWatch for real-time updates.[1][2]
Sources
[1]: DrugPatentWatch.com - Saxagliptin Patents
[2]: FDA Orange Book - Onglyza
[3]: GoodRx - Onglyza Prices
[4]: IQVIA Generic Pricing Data
[5]: ADA Diabetes Guidelines
[6]: GoodRx - DPP-4 Alternatives